ETHYOL Drug Patent Profile

When do Ethyol patents expire, and what generic alternatives are available?

Ethyol is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in ETHYOL is amifostine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amifostine profile page.

Summary for ETHYOL

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for ETHYOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ETHYOL	For Injection	amifostine	500 mg/vial	020221	1	2004-04-16

US Patents and Regulatory Information for ETHYOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	ETHYOL	amifostine	INJECTABLE;INJECTION	020221-002	Sep 10, 1999		DISCN	No	No
Cosette	ETHYOL	amifostine	INJECTABLE;INJECTION	020221-001	Dec 8, 1995		DISCN	Yes	No

International Patents for ETHYOL

See the table below for patents covering ETHYOL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2313089	PROCEDE DE TRAITEMENT DE NEURO ET NEPHRO- TOXICITES ET DE TOXICITES THERAPEUTIQUES PAR DES COMPOSES D'AMINOTHIOL (METHODS FOR TREATMENT OF NEURO- AND NEPHRO- DISORDERS AND THERAPEUTIC TOXICITIES USING AMINOTHIOL COMPOUNDS)
Spain	2215992
Czech Republic	9500230

ETHYOL Market Analysis and Financial Projection

Last updated: February 15, 2026

What Is the Current Investment Scenario for ETHYOL?

Ethyol (amifostine) is a radioprotective and cytoprotective agent approved by the FDA. Its primary use involves reducing the harmful effects of chemotherapy and radiation therapy, particularly in preventing xerostomia and nephrotoxicity.

The market for Ethyol is constrained by limited indications, high production costs, and competition from other protective agents. The drug's sales are primarily driven by its use in oncology treatments, especially for head and neck cancers. As of 2022, its global sales hovered around $100-150 million, with North America accounting for the majority [1].

Key drivers influencing investment include:

• Market Penetration: Limited adoption outside oncology centers.
• Pricing and Reimbursement: Reimbursement policies for supportive cancer therapies influence profit margins.
• Patent Status: Ethyol lost patent exclusivity in 2004, increasing generic competition.
• Regulatory Landscape: No recent FDA label updates or new indications have been recorded post-2020.

Given these factors, Ethyol's outlook centers on conservative growth, with prospects leaning toward lifecycle management rather than breakthrough innovation. Investment values hinge on the drug's ability to maintain or expand its therapeutic niche amid growing competition.

What Are the Fundamental Market Dynamics for Ethyol?

Market Size and Revenue Streams
Global demand for supportive care in oncology expands modestly, projected to grow at an annual rate of 3-4%. Ethyol's share is limited but stable. The total addressed market for radioprotective agents in cancer treatment is estimated at $2 billion worldwide [2].

Competitive Landscape
Other agents, including amifostine alternatives and emerging radioprotectors, infringe on Ethyol’s market segment. No new approvals of Ethyol’s competitors have emerged recently, but pipeline drugs targeting similar indications are advancing.

Pricing and Reimbursement
Pricing varies regionally. In the US, Ethyol is reimbursed under Part B of Medicare, with drug costs often offset by reduced complication treatment costs. However, cost-containment policies threaten margins.

Regulatory Environment
No major regulatory hurdles are evident currently. The absence of new indications or formulations limits revenue growth prospects. The emphasis remains on demonstrating cost-effectiveness and process improvements.

Manufacturing and Cost Structure
Ethyol's manufacturing involves complex chemical synthesis, resulting in higher production costs than generic competitors. Cost reductions are constrained due to the drug's intricate synthesis pathway.

What Are the Investment-Related Risks?

• Market Saturation: The decline in reliance on Ethyol due to improved supportive care alternatives.
• Patent Loss: Absence of patent protection increases vulnerability to generics, pressuring prices.
• Regulatory Changes: Modifications in reimbursement or approval criteria could negatively impact sales.
• Pipeline Competition: Emerging agents with better tolerability and ease of use could displace Ethyol.

What Are the Key Opportunities for Value Enhancement?

• Lifecycle Management: Developing new formulations or delivery methods to extend market lifespan.
• New Indications: Pursuing additional supportive care indications for Ethyol.
• Geographic Expansion: Increasing adoption in emerging markets with expanding cancer care infrastructure.
• Partnerships: Collaborations with biotech firms focusing on novel radioprotectors.

What Are the Strategic Considerations?

• Focus on niche markets where Ethyol still holds dominance, such as specific cancer types.
• Cost-optimization efforts to improve margins amid generic competition.
• Investing in pipeline assets that could complement Ethyol’s profile.

Summary of Fundamentals

Aspect	Details
Market Size (Global)	~$2 billion (supportive oncology agents)
Ethyol's Sales (2022)	~$100-150 million
Patent Status	Expired (2004)
Major Markets	North America, Europe, Asia-Pacific
Growth Rate	Approx. 3-4% annually
Main Competitors	Other radioprotectors, supportive care drugs

Key Takeaways

• Ethyol's revenue relies on niche supportive care indications within oncology.
• Market growth is slow due to generic competition and limited new indications.
• Strategic efforts should focus on lifecycle extension, geographic expansion, and pipeline integration.
• Risks include market saturation, regulatory shifts, and emerging competitors.
• Cost management and partnership development can offer upside potential.

FAQs

1. Is Ethyol a good long-term investment?
Its prospects are limited due to patent expiry, competition, and slow market expansion, making it a cautious investment unless paired with pipeline opportunities.

2. What are the main competitors to Ethyol?
Other supportive care agents like glutathione derivatives and novel radioprotectors in development pipelines.

3. Could new regulations impact Ethyol’s sales?
Yes. Reimbursement reforms or safety concerns could further restrict its market.

4. What markets present growth opportunities for Ethyol?
Emerging markets with expanding oncology services and unmet supportive care needs.

5. How can Ethyol’s patent expiration influence future profitability?
Patent loss exposes the product to generics, eroding margins and sales unless lifecycle strategies are implemented.

References

[1] EvaluatePharma. "Ethyol (amifostine) Market Data," 2022.
[2] MarketWatch. "Radioprotective agents market size," 2022.